Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01885676
Recruitment Status : Unknown
Verified June 2013 by Biotechnology Institute IMASD.
Recruitment status was:  Not yet recruiting
First Posted : June 25, 2013
Last Update Posted : June 25, 2013
Information provided by (Responsible Party):
Biotechnology Institute IMASD

Brief Summary:
  • Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
  • This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Device: PRGF-Endoret Other: Saline Solution Not Applicable

Study Type : Interventional  (Clinical Trial)
Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.
Estimated Primary Completion Date : February 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PRGF-Endoret Device: PRGF-Endoret
PRGF-Endoret mesotherapy micro injection.

Placebo Comparator: Saline Solution Other: Saline Solution
Saline Solution mesotherapy micro injection

Primary Outcome Measures :
  1. Change from baseline in Hair density at three months (number of hairs per cm2) [ Time Frame: 3 months post-treatment ]
    Hair density (number of hairs per cm2) will be measured for each treatment group

Secondary Outcome Measures :
  1. Hair Width (micrometers) [ Time Frame: Basal, 1, 2, and 3 months post-treatment ]
    Hair width will be measured for each treatment group

  2. Anagen/telogen ratio [ Time Frame: Basal, 1, 2, and 3 months post-treatment ]
    Hair cycle has different phases. Two of the most important are anagen (active growth phase of hair follicles) and telogen (resting phase of the hair follicle). This secondary outcome measure allows to measure the efficacy of the PRGF-Endoret treatment.

  3. Terminal Hair Density [ Time Frame: Before each one of the treatments and 1, 2 and 3 months post-treatment. ]
    Terminal hair density will be established for each one of the treatments

  4. Vellous hair density [ Time Frame: Basal,1, 2 and 3 months post-treatment ]
    Vellous hair will be measured for each treatment group

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Androgenetic alopecia according to the following scales:
  • Men: Hamilton/Norwood Scale: grades II-VI
  • Women: Ludwig Scale grades I-II.
  • Possibility of follow-up during the study

Exclusion Criteria:

  • No androgenetic alopecia
  • Telogen and anagen effluvium
  • Active inflammation or infection in the intervention area
  • Presence of active systemic infections.
  • Background of cancerous or precancerous lesions.
  • Background of connective or rheumatic diseases.
  • Suffering from any serious blood disorders.
  • To have undergone treatments for alopecia in the previous 6 months.
  • Previous hair implants
  • Intake of drugs that affect hair loss.
  • Be undergoing immunosuppressive therapy and/or anticoagulants.
  • Known intolerance to mesotherapy.
  • Taking contraceptives containing cyproterone acetate.
  • Pregnancy
  • In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01885676

Contact: Eduardo Anitua, MD, DDS, PhD +34 945160650

Clínica Eduardo Anitua. Not yet recruiting
Vitoria, Alava, Spain, 01007
Contact: Eduardo Anitua, Medical Doctor         
Principal Investigator: Julián Bayón, MD         
Centro dermatológico estético Not yet recruiting
Alicante, Spain, 03014
Contact: Rogelia Navarro, Medical Doctor    965 14 04 60   
Principal Investigator: Rogelia Navarro, MD         
Sponsors and Collaborators
Biotechnology Institute IMASD

Responsible Party: Biotechnology Institute IMASD Identifier: NCT01885676     History of Changes
Other Study ID Numbers: BTI-01D-EC/12/ALO
First Posted: June 25, 2013    Key Record Dates
Last Update Posted: June 25, 2013
Last Verified: June 2013

Additional relevant MeSH terms:
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical
Pharmaceutical Solutions